Across TCGA pan-cancer cohorts, ENO4 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ENO4 data layer compared with 29 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher ENO4 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ENO4 expression acts as an unfavorable survival marker.

ACC and LIHC are the cancer types where ENO4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.066	0.667	.002	12	view →
LIHC	OS	Median	All	0.061	0.783	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: ENO4 tumor-vs-normal RNA expression · all ENO4 data types